Sapient Capital LLC Purchases Shares of 140,371 Elanco Animal Health Incorporated (NYSE:ELAN)

Sapient Capital LLC purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 140,371 shares of the company's stock, valued at approximately $2,092,000.

Several other institutional investors have also recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new stake in shares of Elanco Animal Health in the third quarter valued at $95,000. C M Bidwell & Associates Ltd. purchased a new stake in Elanco Animal Health during the third quarter worth about $129,000. Innovis Asset Management LLC acquired a new stake in shares of Elanco Animal Health during the third quarter worth about $144,000. Ieq Capital LLC boosted its stake in shares of Elanco Animal Health by 10.8% in the third quarter. Ieq Capital LLC now owns 13,464 shares of the company's stock valued at $151,000 after purchasing an additional 1,311 shares during the period. Finally, HBK Sorce Advisory LLC acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at approximately $169,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Up 0.4 %

Shares of NYSE ELAN traded up $0.06 during mid-day trading on Friday, reaching $13.53. The company had a trading volume of 3,719,972 shares, compared to its average volume of 4,351,298. Elanco Animal Health Incorporated has a 52-week low of $7.88 and a 52-week high of $16.88. The stock has a market cap of $6.69 billion, a P/E ratio of -5.41, a PEG ratio of 1.42 and a beta of 1.34. The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The firm has a 50 day simple moving average of $15.08 and a two-hundred day simple moving average of $13.90.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. Elanco Animal Health's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 EPS. Sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ELAN shares. Barclays boosted their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. The Goldman Sachs Group upped their price target on Elanco Animal Health from $12.50 to $14.00 and gave the stock a "sell" rating in a report on Tuesday, February 27th. Stifel Nicolaus upgraded Elanco Animal Health from a "hold" rating to a "buy" rating and lifted their price objective for the company from $13.00 to $20.00 in a research note on Friday, January 5th. Morgan Stanley upped their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Finally, TheStreet upgraded shares of Elanco Animal Health from a "d+" rating to a "c-" rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $16.71.

Insider Transactions at Elanco Animal Health

In related news, Director R David Hoover bought 20,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $16.14 per share, for a total transaction of $322,800.00. Following the purchase, the director now owns 185,000 shares of the company's stock, valued at approximately $2,985,900. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.57% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.